Twenty-four women with fibromyalgia syndrome were randomized to oral cannabis oil containing 10 mg/mL THC and 10 mg/mL CBD in a 1:1 ratio, or a matched placebo oil, taken in the evening. Blood was drawn at five timepoints between enrollment and week 12 of a sixteen-week study window, timed roughly 10 to 14 hours after the prior evening’s dose under fasting conditions to capture a consistent trough state rather than an acute peak.

Rather than asking whether cannabis relieved fibromyalgia pain directly, this analysis asked a narrower mechanistic question: does treatment change three endocannabinoid-related fatty-acid ethanolamides that circulate in plasma and are sometimes proposed as accessible stand-ins for endocannabinoid system activity. The two best-known endocannabinoids, anandamide and 2-AG, were measured but fell below the assay’s limit of detection in this cohort and had to be excluded from the analysis, leaving PEA, OEA, and SEA as the trial’s actual outcome measures.

Using ultra-high-performance liquid chromatography mass spectrometry, the investigators found that mean plasma PEA, OEA, and SEA stayed stable across all five timepoints in both the cannabis and placebo groups. Repeated-measures analysis of variance, with Greenhouse-Geisser correction where needed, showed no significant main effect of time, no significant effect of treatment group, and no significant time-by-group interaction for any of the three markers, with every reported p value above 0.05.

The magnitude of the null result is as notable as its statistical significance. Effect sizes were reported as partial eta squared values of 0.06 or lower across all three outcomes, which the authors describe as minimal. That combination, a well-powered-enough null p value paired with a small effect size, makes a real but undetected effect on these specific markers unlikely, rather than simply unproven.

The abstract notes that clinical benefits were observed with this cannabis treatment even though peripheral NAE levels did not move, a detail drawn from the trial’s broader clinical outcomes rather than from this biomarker sub-analysis itself. Read together, the pairing suggests that whatever symptomatic benefit patients experienced was not accompanied by, and therefore may not depend on, a detectable shift in these particular peripheral blood markers.

That distinction matters for how clinicians think about monitoring. It is tempting to want an objective blood test that confirms a patient is responding to cannabinoid therapy. This trial is evidence that PEA, OEA, and SEA are not that test, at least not in this population, dose, and timeframe. The authors interpret their findings as pointing toward central rather than peripheral mechanisms, consistent with the broader hypothesis that fibromyalgia involves centralized endocannabinoid system dysfunction that a peripheral blood draw cannot easily capture.

This was a pilot trial with 24 women randomized and 22 completers, split evenly into 11 per group. A study this size is well suited to generating a preliminary signal or a well-characterized null result on a specific biomarker question, but it is not powered to detect small differences, examine subgroups, or serve as the final word on endocannabinoid biomarkers in fibromyalgia.

The trial enrolled only women, so the findings should not be assumed to generalize to men with fibromyalgia. It also measured plasma rather than cerebrospinal fluid or central nervous system tissue, and anandamide and 2-AG themselves were undetectable in this cohort’s plasma, which limits how much this specific dataset can say about the endocannabinoid system as a whole rather than the three secondary NAEs it was able to measure.

Endocannabinoid system dysfunction is a leading hypothesis for fibromyalgia’s centralized pain processing, and clinicians have hoped that peripheral blood markers might eventually offer an objective way to track cannabinoid therapy the way a hemoglobin A1c tracks glucose control. This trial is a data point against an easy version of that hope, at least for PEA, OEA, and SEA measured in fasting morning plasma.

Earlier work in the broader NAE literature has found that fibromyalgia patients as a group can show elevated OEA and SEA compared with healthy controls, which makes this trial’s null treatment effect a distinct question from whether NAE levels differ between fibromyalgia patients and the general population. A marker can be altered by having the condition without being altered further by a given treatment.

I welcome negative biomarker results like this one, because they save patients and clinicians from chasing a blood test that will not tell us what we want to know. Fibromyalgia care benefits from honest mechanistic research even when, especially when, the finding is that our current tools cannot yet see what is happening.

The more clinically important sentence in this abstract may be the one about symptom benefit occurring without a peripheral biomarker change. That is consistent with what I see in practice: patients can respond meaningfully to cannabinoid therapy for fibromyalgia without any blood test confirming it, because the relevant activity is happening in the central nervous system, not in a plasma sample.

The Missing Steps Between a Null Biomarker and a Null Treatment Effect